Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

Inclusion Criteria: * Patients with a diagnosis of Parkinson's disease (including juvenile parkinsonism) * Patients who meet all of the following inclusion criteria * Patients who were at least 20 years of age * In- or outpatients of either sex * Patients in any stage on the modified Hoehn and Yahr scale * Patients being treated with L-dopa who have any of the following clinical conditions and problems * Patients with the wearing-off phenomenon * Patients with the on-off phenomenon * Patients to whom a sufficient amount of L-dopa cannot be administered owing to the occurrence of an adverse event * Patients in whom the effect of L-dopa is attenuated * Patients in whom a dose increase of L-dopa has been refrained * Patients with freezing phenomenon Exclusion Criteria: * Patients being treated with other dopamine agonists (bromocriptine, pergolide mesylate, talipexole hydrochloride). Patients who have been treated with other dopamine agonist for at least 4 weeks before the start of the study (the day of giving informed consent) are eligible for the study * Patients with a history of hypersensitivity to ergot preparations * Patients with psychiatric symptoms such as confusion, hallucination, delusion, excitement, delirium, and abnormal behaviour * Patients with subjective symptoms derived from orthostatic hypotension * Patients with hypotension (systolic blood pressure less than 100 mmHg) * Patients wiht Raynaud disease * Patients with peptic ulcer * Patients with complications such as severe cardiac, renal, hepatic disease etc. * Patients with a current or past history of epilepsy * Women who are or may be pregnant and lactating women * Patients who are receiving any other investigational products or who have received any other investigational product within 6 months of the study * Patients who are incompetent to give consent * Others judged by the investigator or co-investigator to be ineligible as subjects